1 Report Overview

1.1 Biosimilar Overview

1.1.1 Global Biosimilars Market Forecast, 2020-2030

1.2 Biosimilars Market Segmentation

1.3 Why You Should Read this Report

1.4 Main Questions Answered by this Report

1.5 Who is this Report for?

1.6 Research and Analysis Methods

1.7 Frequently Asked Questions (FAQ)

1.8 Some Associated Reports

1.9 About Visiongain

2 An Introduction to Biosimilars and Biosimilar Drug Development

2.1 What are Biologics?

2.1.1 Biologics Can Be Very Effective but Also Very Expensive

2.1.2 Brief History of Biological Drug Development

2.1.3 Why are Biologics the Most Lucrative Products in The Global Pharmaceutical Market?

2.2 What are Biosimilars?

2.3 Brief History of Biosimilars

2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?

2.4.1 FDA Guidelines on Prescription of Interchangeables Vs Biosimilars

2.4.2 Where Does the EMA Stand with Regard to Interchangeables?

2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?

2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?

2.5 Main Segments of the Overall Biosimilars Market

2.6 Definitions

2.6.1 EMA Terminology Related to Biosimilars

2.6.2 FDA Terminology Related to Biosimilars

2.6.3 WHO Terminology Related to Biosimilars

2.6.4 Differences Between Common Drug Classifications

3 Market and Technology Background

3.1 Lifecycle of a Biosimilar Drug

3.2 Development of a Biosimilar

3.2.1 Cell Line Development and Selection

3.2.2 E. coli Cells

3.3 Mammalian Cells

3.4 Manufacturing of a Biosimilar

3.5 Preclinical Studies and Validation of a Biosimilar

3.6 Clinical Trials

3.7 Approval by Regulatory Agencies

3.8 Pharmacovigilance/Post-Approval Monitoring

4 Global Biosimilar Market by Type

4.1 Global Biosimilars Market Forecast by Submarket, 202 b0-2030

4.2 Recombinant Hormones

4.2.1 Human Growth Hormone: First Extracted in 1958

4.2.2 Biosimilar Growth Hormones Market Forecast, 2020-2030

4.3 Fertility Hormones

4.3.1 Two Products Lead the Branded Fertility Hormone Market

4.3.2 Long-Acting Follicle Stimulating Hormone (FSH)

4.3.3 Branded Fertility Hormones Market Outlook

4.3.4 Rising Infertility to Drive Demand to 2030

4.3.5 Biosimilar Fertility Hormones Market Forecast, 2020-2030

4.3.6 Human Growth Hormone (HGH)

4.3.7 Follicle-Stimulating Hormone (FSH)

4.4 Recombinant Growth Factors

4.4.1 Erythropoietin (EPO)

4.4.2 Biosimilar EPO Market Forecast, 2020-2030

4.4.3 Granulocyte-Colony Stimulating Factor (G-CSF)

4.4.4 Biosimilar EPO Market Forecast, 2020-2030

4.5 Insulin

4.5.1 Global Biosimilar Insulin Revenue Forecast, 2020-2030

4.5.2 Global Biosimilar Insulin Market Share, 2020-2030

4.5.3 Biosimilar Human Insulin Submarket Forecast, 2020-2030

4.5.4 Biosimilar Insulin Analogues Submarket, 2020-2030

4.5.5 Biosimilar Insulin Analogue Revenue Forecast, 2020-2030

4.6 Biosimilar Insulin Glargine

4.6.1 Biosimilar Insulin Glargine: Revenue Forecast, 2020-2030

4.7 Biosimilar Insulin Lispro

4.7.1 Biosimilar Insulin Lispro: Revenue Forecast, 2020-2030

4.8 Monoclonal Antibodies (mAbs)

4.8.1 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2020-2030

4.8.2 Global Biosimilar Monoclonal Antibodies Market Share, 2020-2030

4.8.3 Biosimilar Rituximab

4.8.4 Biosimilar Infliximab

4.8.5 Biosimilar Trastuzumab

4.8.6 Biosimilar Adalimumab

4.8.7 Biosimilar Bevacizumab

4.9 Fusion Proteins

4.10 Interferons

4.10.1 Biosimilar Interferon Market Forecast, 2020-2030

4.10.2 Global Biosimilar Interferons Market Share, 2020-2030

4.11 Biosimilar Interferon Alfa

4.11.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, leading to Fragmented Markets

4.11.2 Biosimilar Peginterferon Alfa

4.11.3 Biosimilar Interferon Alfa Submarket Forecast, 2020-2030

4.12 Biosimilar Interferon Beta

4.12.1 Biosimilars are Well-Established in Emerging Markets

4.12.2 Biosimilar Interferon Beta Pipeline

4.12.3 Long-Acting Interferon Beta

4.12.4 Biosimilar Interferon Beta Submarket Forecast, 2020-2030

4.13 Strategies to Develop Biobetters

4.13.1 PEGylation

4.13.2 Glycosylation

4.13.3 Fusion Proteins

4.14 Others

4.14.1 Low Molecular Weight Heparins

4.15 FDA Guidance to LMWH Biosimilars

4.15.1 EMA Guidance to LMWH Biosimilars

5 Biosimilars: Qualitative Analysis and Industry Trends

5.1 Analysis of Market Opportunities

5.2 Strengths of Biosimilars Market

5.2.1 Growing Aging Population

5.2.2 Rising Incidence of Diseases

5.2.3 Patent Expirations

5.2.4 Growing Pipeline

5.2.5 Drive to Reduce Costs

5.2.6 Government Incentives

5.2.7 Incentives in Europe

5.2.8 Incentives in Indian Market

5.2.9 Collaborations and Partnerships

5.2.10 Mergers and Acquisitions

5.3 Weaknesses of Biosimilars Market

5.3.1 Manufacturing Process of Biosimilars

5.3.2 Process Definition and Testing and Validation

5.3.3 Lack of Skilled Personnel

5.3.4 Regulatory Guidelines

5.3.5 Interchangeability

5.3.6 Nomenclature of Biosimilars

5.3.7 Patent Litigation

5.4 Threats in Biosimilars Market

5.4.1 Unpredictable Regulatory Landscape

5.4.2 Prescription by Medical Practitioners/Pharmacies

5.4.3 Competition

5.5 Opportunities in Biosimilars Market

5.5.1 Emerging Markets

5.5.2 Technological Innovation and Improved Process Knowledge

5.5.3 Pricing

5.6 Biosimilars Product Pipeline

6 Global Biosimilars and Follow-on Biologics Market Breakdown by Application

6.1 Market by Biosimilar Applications

6.1.1 Global Biosimilar Market by Application: Revenue Forecast, 2020-2030

6.1.2 Global Biosimilar Application Market Share, 2020-2030

6.2 Cancer Biosimilars

6.2.1 Market Overview

6.3 Blood Disorders

6.3.1 Market Overview

6.3.2 Market Revenue

6.4 Diabetes

6.4.1 Market Overview

6.4.2 Market Revenue

6.5 Growth Hormone Deficiency

6.5.1 Market Overview

6.5.2 Market Revenue

6.6 Infectious Diseases

6.6.1 Market Overview

6.6.2 Market Revenue

6.7 Autoimmune Diseases

6.7.1 Market Overview

6.7.2 Market Revenue

6.8 Other Diseases

6.8.1 Market Overview

6.8.2 Market Revenue

7 Global Biosimilars Market Outlook by Country, 2020-2030

7.1 National Submarket Forecasts 2020-2030

7.1.1 Global Biosimilar Market by Nation: Revenue Forecast, 2020-2030

7.2 Regional Market Overview

7.2.1 Global Biosimilar Market Share by Nation, 2020-2030

7.3 US Biosimilars Market Outlook 2020-2030

7.3.1 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015

7.3.2 FDA Finally Releases Guidance on Biosimilar Naming

7.3.3 Individual States Can Pass their Own Biosimilar Substitution Laws

7.3.4 US Biosimilars Market Forecast 2020-2030

7.4 Canada Biosimilar Market Outlook, 2020

7.4.1 Canada Biosimilar Market Forecast, 2020-2030

7.5 The EU Biosimilar Market: History and Current Status

7.5.1 History of EMA Guidelines and Updates

7.5.2 Biosimilar Uptake in Europe Varies between Nations

7.5.3 European Biosimilars Market Forecast, 2020-2030

7.5.4 Inflectra and Remsima in Europe - Demonstrates a Path for Other Biosimilar mAbs

7.6 German Biosimilar Market Outlook, 2020

7.6.1 German Biosimilar Market Forecast, 2020-2030

7.7 French Biosimilars Market Outlook, 2020

7.7.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year

7.7.2 French Biosimilar Market Forecast, 2020-2030

7.8 UK Biosimilar Market Outlook, 2020

7.8.1 UK Biosimilar Market Forecast, 2020-2030

7.9 Italian Biosimilars Market Outlook, 2020

7.9.1 Italian Biosimilars Market Forecast, 2020-2030

7.10 Spanish Biosimilars Market Outlook, 2020

7.10.1 Spanish Biosimilar Market Forecast, 2020-2030

7.11 Sweden Biosimilars Market Outlook, 2020

7.11.1 Sweden Biosimilar Market Forecast, 2020-2030

7.12 Norway Biosimilars Market Outlook, 2020

7.12.1 Norway Biosimilar Market Forecast, 2020-2030

7.13 Japan Biosimilars Market Outlook, 2020

7.13.1 Biosimilar Regulation in Japan and Currently Approved Biosimilars

7.13.2 Differences between the European and Japanese Guidelines

7.13.3 Currently Approved Biosimilars in Japan

7.13.4 Japanese Biosimilar Market Forecast, 2020-2030

8 Outlook for Biosimilars in Emerging Markets, 2020-2030

8.1 China and India Lead Biosimilar Revenues

8.2 Leading Emerging Biosimilar Markets Forecast, 2020-2030

8.3 Chinese Biosimilars Market Outlook, 2020

8.3.1 China Publishes Final Guidelines for Biosimilars

8.3.2 Chinese Biosimilars Market Forecast, 2020-2030

8.4 Indian Biosimilars Market Outlook, 2020

8.4.1 CDSCO Guidelines Released in 2012

8.4.2 Indian Biosimilars Market Forecast, 2020-2030

8.5 South Korea’s Established Biosimilar Guidelines

8.5.1 Currently Approved Biosimilars in South Korea, 2019

8.6 Russian Biosimilars Market Outlook and Forecast, 2020-2030

8.7 Brazilian Biosimilars Market Outlook and Forecast, 2020-2030

8.7.1 Brazilian Biosimilar Regulation

8.7.2 Government Eager to Promote Biosimilar Development, And Two Major Conglomerates, Bionovis And Orygen, Are Racing to Produce Biosimilars

8.7.3 Brazilian Biosimilars Market Forecast, 2020-2030

8.8 South Africa Biosimilars Market Outlook, 2020

8.8.1 South Africa Biosimilar Market Forecast, 2020-2030

8.9 Australia Biosimilars Market Outlook, 2020

8.9.1 Australia Biosimilar Market Forecast, 2020-2030

9 Industry Structure

9.1 Types of Market Players

9.1.1 Established Biologics Companies

9.1.2 Established Generics Companies

9.1.3 Bio-intellectual Companies

9.1.4 Opportunistic Companies

9.2 Emerging Trends in Biosimilar Industry Structure

9.2.1 Collaborations and Partnerships

9.2.2 Mergers and Acquisitions

9.2.3 Contract Manufacturing Organizations (CMOs)

9.3 Losses of Exclusivity- A Determining Factor

9.4 Biosimilar Market Entry Dates

9.5 Biosimilars in the Pipeline

9.5.1 Humira (adalimumab)

9.5.2 Enbrel (etanercept)

9.5.3 Lucentis (ranibizumab)

9.5.4 Actemra IV (tocilizumab)

9.5.5 Eylea (aflibercept)

9.6 Outsourcing Biosimilar Development

9.6.1 A Biosimilar Company Perspective

9.6.2 Business Model Differences

10 Leading Manufacturers/Suppliers of Biosimilar Drugs

10.1 Market Share

10.2 Recombinant Growth Factors

10.2.1 Market Share

10.3 Monoclonal Antibodies

10.3.1 Market Share

10.4 Fusion Proteins

10.4.1 Market Share

10.5 Others

10.5.1 Market Share

11 Company Profiles

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Company Financials

11.1.3 Company Recent Developments

11.2 Biocon Limited

11.2.1 Company Overview

11.2.2 Company Financials

11.2.3 Company Recent Developments

11.3 Celltrion Healthcare Co. Ltd.

11.3.1 Company Overview

11.3.2 Company Financials

11.3.3 Company Recent Developments

11.4 Dong-A Socio Holdings

11.4.1 Company Overview

11.4.2 Company Financials

11.4.3 Company Recent Developments

11.5 Dr. Reddy’s Laboratories Ltd.

11.5.1 Company Overview

11.5.2 Company Financials

11.5.3 Company Recent Developments

11.6 F Hoffmann-La Roche Ltd.

11.6.1 Company Overview

11.6.2 Company Financials

11.6.3 Company Recent Developments

11.7 Pfizer Inc.

11.7.1 Company Overview

11.7.2 Company Financials

11.7.3 Company Recent Developments

11.8 Stada Arzneimittel AG

11.8.1 Company Overview

11.8.2 Company Financials

11.8.3 Company Recent Developments

11.9 Teva Pharmaceutical Industries Ltd.

11.9.1 Company Overview

11.9.2 Company Financials

11.9.3 Company Recent Developments

11.10 Wockhardt Limited

11.10.1 Company Overview

11.10.2 Company Financials

11.10.3 Company Recent Developments

11.11 3S BIO INC.

11.11.1 Company Overview

11.11.2 Company Financials

11.12 CELLTRION INC.

11.12.1 Company Overview

11.12.2 Company Financials

11.13 GENEXINE INC.

11.13.1 Company Overview

11.14 MYLAN N.V.

11.14.1 Company Overview

11.14.2 Company Financials

11.15 ZYDUS CADILA

11.15.1 Company Overview

11.15.2 Company Financials

11.16 NIPPON KAYAKU CO. LTD.

11.16.1 Company Overview

11.16.2 Company Financials

11.17 MABXIENCE S.A.

11.17.1 Company Overview

11.18 LG LIFE SCIENCES

11.18.1 Company Overview

11.19 Intas Pharmaceuticals Ltd.

11.19.1 Company Overview

11.20 Gedeon Richter Plc

11.20.1 Company Overview

12 Global Biosimilar Patent Review

12.1 Patent Regulations in Favour of Branded Biologics

12.2 Market Exclusivity

12.2.1 Patent Dance

12.2.2 Licensing Notice

12.3 Patent Regulations in Favour of Biosimilars-Emerging Trends

12.3.1 Market Exclusivity Option

12.4 Patent Dance Developments

12.4.1 Licensing Notice

12.4.2 Product vs Process Patents

12.5 Patent Activity in Biosimilars, 2015-2019

12.5.1 United States Patents

12.5.2 Patents by Type

13 New Developments in Global Biosimilars Market

13.1 Major Companies in the Biosimilars Market

13.2 Biosimilars in Clinical Trials

13.3 Overview

13.3.1 Biosimilar Recombinant Hormones in Clinical Trials

13.4 Biosimilar Recombinant Growth Factors in Clinical Trials

13.5 Biosimilar Monoclonal Antibodies in Clinical Trials

13.6 Biosimilar Fusion Proteins in Clinical Trials

13.7 Other Biosimilars in Clinical Trials

13.8 Bio-betters in Clinical Trials

13.9 Significant Regulatory Activities

14 COVID-19 Impact on The Pharmaceutical Supply Chain

14.1 COVID-19 Impact on the Biosimilar Supply Chain

14.2 Health Care Services (HCPS) And Other Health Policy-Makers Unavailable:

14.3 Biosimilars See Some Positive Momentum, Despite Covid-19

14.4 Future Changes to Manufacturing Practices

15 Conclusions from Visiongain’s Research and Analysis

15.1 Rapid Growth Expected for this High-Potential Market

15.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment

15.3 A Range of Factors Will Stimulate Demand

15.4 Challenges Remain in Developing and Successfully Launching Biosimilars

Some Associated Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Tables

Table 1.1 Global Biosimilars Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993

Table 2.2 Small Molecular Drugs vs. Biologics

Table 2.3 Generics vs. Biosimilars

Table 2.4 Biosimilars vs. Biobetters

Table 3.1 List of Biosimilars Produced in E. Coli

Table 3.2 List of Biosimilars Produced in Mammalian Cells

Table 3.3 Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)

Table 3.4 US Approved Biosimilars As of December 2019

Table 4.1 Biosimilars Market Forecast by Product Type: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 4.2 Biosimilar Growth Hormone Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.3 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2030

Table 4.4 Biosimilar Recombinant Hormones

Table 4.5 Biosimilar EPO Market Forecast: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 4.6 Biosimilar Recombinant Growth Factors

Table 4.7 Biosimilar G-CSF Market Forecast: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 4.8 Biosimilar Insulin Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.9 Biosimilar Human Insulin Submarkets Forecast: Revenue ($billion), AGR (%), CAGR (%), 2019-2030

Table 4.10 Biosimilar Insulin Analogues Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.11 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.12 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.13 Biosimilar Monoclonal Antibodies

Table 4.14 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.15 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.16 Biosimilar Rituximab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.17 Biosimilar Infliximab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.18 Biosimilar Trastuzumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.19 Biosimilar Adalimumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.20 Biosimilar Bevacizumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.21 Biosimilar Fusion Proteins

Table 4.22 Fusion Proteins Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.23 Biosimilar Interferons Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.24 Selected Interferon Alfa Biosimilars Approved Worldwide, 2019

Table 4.25 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.26 Selected Interferon Beta Biosimilars Approved Worldwide

Table 4.27 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 4.28 Biosimilar LMWHs

Table 5.1 Biosimilars Product Pipeline

Table 6.1 Global Biosimilar Application Revenue Forecast by Type: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.2 Cancer Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.3 Blood Disorder Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.4 Diabetes Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.5 GHD Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.6 Infectious Disease Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.7 Autoimmune Diseases Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 6.8 Other Diseases Biosimilar Application Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 7.1 Biosimilars Market Forecast by Nations: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.2 US Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.3 Canada Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.4: European Biosimilar Approvals To-Date, 2019

Table 7.5 European Biosimilar Market Segmented by Leading Nations: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 7.6 Germany Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 7.7 France Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.8 UK Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 7.9 Italy Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 7.10 Spain Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.11 Sweden Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.12 Norway Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 7.13: Japanese Biosimilar Approvals To-Date, 2019

Table 7.14 Japan Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 8.1 Leading Emerging Biosimilar Markets: Revenue ($billion), AGR (%), CAGR (%), Market Share (%), 2020-2030

Table 8.2 China Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 8.3 India Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 8.4: Currently Approved Biosimilars in South Korea, 2019

Table 8.5 South Korea Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 8.6 Russia Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 8.7 Comparison of Brazilian regulations for follow-on biologicals with EMA, FDA and WHO

Table 8.8 Brazil Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 8.9 South Africa Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030

Table 8.10 Australia Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030

Table 9.1 Mergers and Acquisitions in the Biosimilars Market, 2015-2020

Table 10.1 Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019

Table 10.2 Global Market Shares of Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019 (%)

Table 10.3 Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019

Table 10.4 Global Market Shares of Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019 (%)

Table 10.5 Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019

Table 10.6 Global Market Shares of Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019 (%)

Table 10.7 Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019

Table 10.8 Global Market Shares of Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019 (%)

Table 10.9 Leading Manufacturers/Suppliers of Other Biosimilars, 2019

Table 10.10 Global Market Shares of Leading Manufacturers/Suppliers of Other Biosimilars, 2019 (%)

Table 11.1 Amgen Inc. Profile 2019

Table 11.2 Company Financials, 2013-2018, USD Million

Table 11.3 Amgen: Key Developments

Table 11.4 Biocon Limited Profile 2020

Table 11.5 Biocon Limited Profile 2020

Table 11.6 Biocon Limited: Key Developments

Table 11.7 Celltrion Healthcare Co. Ltd. Profile 2019

Table 11.8 Company Financials, 2014-2018, USD Million

Table 11.9 Celltrion Healthcare: Key Developments

Table 11.10 Dong-A Socio Holdings Profile 2019

Table 11.11 Company Financials, 2014-2018, USD Million

Table 11.12 Dong-ASocio Holdings: Key Developments

Table 11.13 Dr. Reddy’s Laboratories Ltd. Profile 2020

Table 11.14 Company Financials, 2015-2019, USD Million

Table 11.15 Dr. Reddy’s Laboratories: Key Developments

Table 11.16 F Hoffmann-La Roche Ltd. Profile 2019

Table 11.17 Company Financials, 2014-2018, USD Million

Table 11.18 Roche Holding AG.: Key Developments

Table 11.19 Pfizer Inc. Profile 2019

Table 11.20 Company Financials, 2014-2018, USD Million

Table 11.21 Pfizer, Inc.: Key Developments

Table 11.22 Stada Arzneimittel AG Profile 2019

Table 11.23 Company Financials

Table 11.24 Stada: Key Developments

Table 11.25 Teva Pharmaceutical Industries Ltd. Profile 2019

Table 11.26 Company Financials, 2014-2018, USD Million

Table 11.27 Teva: Key Developments

Table 11.28 Wockhardt Limited Profile 2019

Table 11.29 Company Financials, 2017-2018, USD Million

Table 11.30 Wockhardt Limited: Key Developments

Table 11.31 Company Financials, 2016-2018, USD Million

Table 11.32 Company Financials, 2014-2018, USD Million

Table 11.33 Company Financials, 2014-2018, USD Million

Table 11.34 Company Financials, 2016-2019, USD Million

Table 11.35 Company Financials, 2015-2019, USD Million

Table 12.1 Inter Partes Review (IPR) Challenges by Biosimilar Developers

Table 12.2 Patents for Biosimilars, by Year, 2015-November 2019 (Number)

Table 12.3 Patents for Biosimilars, by Type, 2015-November 2019 (Number)

Table 12.4 US Approved Biosimilars

Table 12.5 European Approvals of Biosimilars

Table 13.1 Major Companies with Biosimilars in Pipeline

Table 13.2 Major Biosimilar Candidates with Patent Expirations

Table 13.3 Biosimilars in Various Phases of Clinical Trials, by Type

Table 13.4 Biosimilar Recombinant Hormones in Clinical Trials

Table 13.5 Biosimilar Recombinant Growth Factors in Clinical Trials

Table 13.6 Biosimilar Monoclonal Antibodies in Clinical Trials

Table 13.7 Biosimilar Fusion Proteins in Clinical Trials

Table 13.8 Other Biosimilars in Clinical Trials

Table 13.9 Representative Bio-betters in Clinical Trials

Table 13.10 List of Approved Biosimilar Drugs, by Country

List of Figures

Figure 1.1 Global Biosimilars Market Forecast: Revenue ($billion), 2020-2030

Figure 1.2 Main Segments and Sub-Segments of the Biosimilars Market, 2020

Figure 4.1 Global Biosimilars Market Forecasts by Submarket: Revenue ($billion), 2020-2030

Figure 4.2 Global Biosimilars Market Forecasts by Submarket: Revenue ($billion), 2020-2030

Figure 4.3 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), 2020-2030

Figure 4.4 Biosimilar EPO Market Forecast: Revenue ($billion), 2020-2030

Figure 4.5 Biosimilar G-CSF Market Forecast: Revenue ($billion), 2020-2030

Figure 4.6 Biosimilar Insulin Market Forecast: Revenue ($billion), 2020-2030

Figure 4.7 Biosimilar Insulin Market Share Forecast 2020

Figure 4.8 Biosimilar Insulin Market Share Forecast 2025

Figure 4.9 Biosimilar Insulin Market Share Forecast 2030

Figure 4.10 Biosimilar Human Insulin Submarket Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.11 Biosimilar Insulin Analogues Market Forecast: Revenue ($billion), 2020-2030

Figure 4.12 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.13 Biosimilar Insulin Submarket Forecast: Revenue ($billion), 2020-2030

Figure 4.14 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($billion), 2020-2030

Figure 4.15 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($billion), 2020-2030

Figure 4.16 Biosimilar Monoclonal Antibodies Market Share Forecast 2020

Figure 4.17 Biosimilar Monoclonal Antibodies Market Share Forecast 2025

Figure 4.18 Biosimilar Monoclonal Antibodies Market Share Forecast 2030

Figure 4.19 Biosimilar Rituximab Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.20 Biosimilar Infliximab Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.21 Biosimilar Trastuzumab Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.22 Biosimilar Adalimumab Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.23 Biosimilar Bevacizumab Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.24 Fusion Proteins Revenue Forecast: Revenue ($billion), 2020-2030

Figure 4.25 Biosimilar Interferons Market Forecast: Revenue ($billion), 2020-2030

Figure 4.26 Biosimilar Interferons Market Share Forecast 2020

Figure 4.27 Biosimilar Interferons Market Share Forecast 2025

Figure 4.28 Biosimilar Interferons Market Share Forecast 2030

Figure 4.29 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), 2020-2030

Figure 4.30 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), 2020-2030

Figure 5.1 SWOT Analysis of Biosimilar Market

Figure 6.1 Global Biosimilar Application Revenue Forecast by Type: Revenue ($billion), 2020-2030

Figure 6.2 Global Biosimilar Application Market Share Forecast 2020

Figure 6.3 Global Biosimilar Application Market Share Forecast 2025

Figure 6.4 Global Biosimilar Application Market Share Forecast 2030

Figure 6.5 Cancer Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.6 Blood Disorder Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.7 Diabetes Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.8 GHD Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.9 Infectious Disease Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.10 Autoimmune Diseases Biosimilar Revenue Forecast: Revenue ($billion), 2020-2030

Figure 6.11 Other Diseases Biosimilar Application Revenue Forecast: Revenue ($billion), 2020-2030

Figure 7.1 Global Biosimilars Market Forecasts by Nations: Revenue ($billion), 2020-2030

Figure 7.2 Global Biosimilar Market Share by Nation Forecast 2020

Figure 7.3 Global Biosimilar Market Share by Nation Forecast 2025

Figure 7.4 Global Biosimilar Market Share by Nation Forecast 2030

Figure 7.5 US Biosimilars Market: Revenue ($billion), 2020-2030, AGR (%)

Figure 7.6 Canada Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.7 European Biosimilars Market Segmented by Leading Nations: Revenue ($billion), 2020-2030

Figure 7.8 Germany Biosimilars Market: Revenue ($bn), 2019-2030

Figure 7.9 France Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.10 UK Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.11 Italy Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.12 Spain Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.13 Sweden Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.14 Norway Biosimilars Market: Revenue ($billion), 2020-2030

Figure 7.15 Japan Biosimilars Market: Revenue ($bn), 2020-2030

Figure 8.1 Leading Emerging Nations Biosimilar Market Shares: Revenues ($billion), 2019-2030

Figure 8.2 China Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.3 India Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.4 South Korea Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.5 Russia Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.6 Brazil Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.7 South Africa Biosimilars Market: Revenue ($billion), 2020-2030

Figure 8.8 Australia Biosimilars Market: Revenue ($billion), 2020-2030

Figure 9.1 Developed Markets Impact of Brand Losses of Exclusivity, 2013-2022, USD Bn

Figure 9.2 US Impact of Brand Losses of Exclusivity, 2013-2022, USD Bn

Figure 10.1 Global Market Shares of Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019

Figure 10.2 Global Market Shares of Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019

Figure 10.3 Global Market Shares of Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019 (%)

Figure 10.4 Global Market Shares of Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019 (%)

Figure 10.5 Global Market Shares of Leading Manufacturers/Suppliers of Other Biosimilars, 2019 (%)

Figure 11.1 Company Financials, 2013-2018, USD Million

Figure 11.2 Company Financials, 2015-2018, USD Million

Figure 11.3 Company Financials, 2014-2018, USD Million

Figure 11.4 Company Financials, 2014-2018, USD Million

Figure 11.5 Company Financials, 2015-2019, USD Million

Figure 11.6 Company Financials, 2014-2018, USD Million

Figure 11.7 Company Financials, 2014-2018, USD Million

Figure 11.8 Company Financials, 2014-2018, USD Million

Figure 11.9 Company Financials, 2014-2018, USD Million

Figure 11.10 Company Financials, 2017-2018, USD Million

Figure 11.11 Company Financials, 2016-2018, USD Million

Figure 11.12 Company Financials, 2014-2018, USD Million

Figure 11.13 Company Financials, 2014-2018, USD Million

Figure 11.14 Company Financials, 2016-2019, USD Million

Figure 11.15 Company Financials, 2015-2019, USD Million

Figure 12.1 Top 10 selling biologics patent cliff (2000–2020)